PURPOSE: Heavy-atom-enhanced synchrotron stereotactic radiotherapy (SSR) is a treatment that involves selective accumulation of high-Z elements in tumors followed by stereotactic irradiation with X-rays from a synchrotron source. The purpose of this study was to determine whether the efficacy of iodine-enhanced SSR could be further improved in the F98 rodent glioma model, by using a concomitant injection of an iodinated contrast agent and a transient blood-brain barrier opener (mannitol) during irradiation. METHODS AND MATERIALS: Fourteen days after intracerebral inoculations of F98 cells, the rats were irradiated with 50-keV X-rays while receiving an infusion of hyperosmotic mannitol with iodine, either intravenously or via the carotid (9 to 15 rats per group, 117 rats total). RESULTS: For doses<or=15 Gy, the intracarotid infusion of mannitol and iodine improved the rats' survival compared with intravenous injection or irradiation alone. The percentage-increased life spans (ILS) were 91%, 116%, and 169% without iodine, after infusion of iodine and mannitol intravenously, and intracarotid, respectively (15 Gy). At 25 Gy, the rats irradiated without iodine had the longest survival (ILS=607%), but no additional benefit was obtained with iodine and mannitol. CONCLUSIONS: Iodine-enhanced SSR is significantly improved with concomitant intracarotid infusion of iodine and mannitol for radiation doses<or=15 Gy.
PURPOSE: Heavy-atom-enhanced synchrotron stereotactic radiotherapy (SSR) is a treatment that involves selective accumulation of high-Z elements in tumors followed by stereotactic irradiation with X-rays from a synchrotron source. The purpose of this study was to determine whether the efficacy of iodine-enhanced SSR could be further improved in the F98 rodent glioma model, by using a concomitant injection of an iodinated contrast agent and a transient blood-brain barrier opener (mannitol) during irradiation. METHODS AND MATERIALS: Fourteen days after intracerebral inoculations of F98 cells, the rats were irradiated with 50-keV X-rays while receiving an infusion of hyperosmotic mannitol with iodine, either intravenously or via the carotid (9 to 15 rats per group, 117 rats total). RESULTS: For doses<or=15 Gy, the intracarotid infusion of mannitol and iodine improved the rats' survival compared with intravenous injection or irradiation alone. The percentage-increased life spans (ILS) were 91%, 116%, and 169% without iodine, after infusion of iodine and mannitol intravenously, and intracarotid, respectively (15 Gy). At 25 Gy, the rats irradiated without iodine had the longest survival (ILS=607%), but no additional benefit was obtained with iodine and mannitol. CONCLUSIONS:Iodine-enhanced SSR is significantly improved with concomitant intracarotid infusion of iodine and mannitol for radiation doses<or=15 Gy.
Authors: Xiaogang Pan; Gong Wu; Weiliang Yang; Rolf F Barth; Werner Tjarks; Robert J Lee Journal: Bioconjug Chem Date: 2007 Jan-Feb Impact factor: 4.774
Authors: Julia Rousseau; Rolf F Barth; Manuel Fernandez; Jean-François Adam; Jacques Balosso; François Estève; Hélène Elleaume Journal: J Neurooncol Date: 2009-12-11 Impact factor: 4.130
Authors: Julia Rousseau; Caroline Boudou; Rolf F Barth; Jacques Balosso; François Estève; Hélène Elleaume Journal: Clin Cancer Res Date: 2007-08-28 Impact factor: 12.531
Authors: James F Hainfeld; Henry M Smilowitz; Michael J O'Connor; Farrokh Avraham Dilmanian; Daniel N Slatkin Journal: Nanomedicine (Lond) Date: 2012-12-24 Impact factor: 5.307
Authors: B H Laster; C Isaacson; E Perets; M Msamra; E Priel; J Kalef-Ezra; J Kost Journal: J Cancer Res Clin Oncol Date: 2014-07-30 Impact factor: 4.553